NEO(NeoGenomics, Inc.) 的财务报表:医疗保健,诊断与研究。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $484.33M | $509.73M | $591.64M | $660.57M | $727.33M |
| 毛利润 | $187.06M | $187.90M | $244.60M | $290.10M | $314.29M |
| 营业利润 | −$118.75M | −$157.62M | −$107.74M | −$92.11M | −$115.88M |
| 净利润 | −$8.35M | −$144.25M | −$87.97M | −$78.73M | −$108.03M |
| 经营现金流 | −$26.72M | −$65.99M | −$1.95M | $7.02M | $5.23M |
| 自由现金流 | −$90.86M | −$96.88M | −$30.70M | −$34.04M | −$21.78M |
| 摊薄每股收益 | — | — | — | — | — |